ClinicalTrials.gg
RecruitingNCT05844462ERASE PH-COPDUpdated Aug 20, 2026

Tadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease

A Phase 3 interventional study of Tadalafil and Placebo in Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies testing tadalafil in Hypertension, Pulmonary — 3 open to participants now, 3 under way, 2 of them phase 3. Tadalafil · Hypertension, Pulmonary.

Planned enrollment
5th of 18
200 · median 40
Started
2024
with 1 other
Phase 3
8 of 18
2 open now
Registered
16th of 18
by date
Lead sponsor
1 of 18
Assistance Publique - Hôpitaux de Paris

Among the 18 studies testing tadalafil in Hypertension, Pulmonary, this one is the 5th largest by planned enrollment, is one of 2 that started in 2024, is one of 8 in phase 3, and was the 16th registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

3 of the 18 studies testing tadalafil in Hypertension, Pulmonary are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About tadalafil

Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 163 Hypertension, Pulmonary studies recruiting now, 98 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 38 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing tadalafil in Hypertension, Pulmonary, or all of them as a file.
02

Study summary

ERASE PH-COPD is a randomized double-blind study, with 2 parallel groups. Patients with severe pulmonary hypertension due to chronic obstructive pulmonary disease, will be randomly assigned to receive Tadalafil orally or placebo.

Read the detailed description

Pulmonary hypertension (PH) is a frequent complication of chronic parenchymal lung diseases particularly in chronic obstructive pulmonary disease (COPD) and represents one of the major cause of all causes of PH. When present, PH contributes to more severe symptoms; exercise intolerance and can lead to right heart failure, which portends a worse prognosis and an increased mortality. Mechanisms of severe PH in chronic respiratory diseases are complex and include rarefaction of vascular bed, endothelial dysfunction and exaggerated pulmonary arterial remodeling. In patients with idiopathic pulmonary arterial hypertension (PAH), targeted medical therapies, including oral phosphodiesterase type 5 inhibitors (PDE5i), improve endothelial cell dysfunction, have vasodilatory and anti-proliferative effects on the pulmonary vasculature, reduce the right ventricular afterload and improve symptoms, exercise capacity, and clinical outcomes in randomized trials. Several studies suggested a potential effect of PDE5i in COPD on dyspnea, exertional capacity and quality of life. However, these results were based on including small number of patients with heterogenous severity of lung disease and usually without complete hemodynamic evaluation. Data are lacking regarding the benefit/risk ratio of these treatments in the context of severe PH due to COPD. The main objective to this randomized controlled trial (16 weeks) is to evaluate the efficacy and safety of an oral PDE5i, tadalafil, in patients with severe PH due to COPD.

03

Conditions studied

  • Pulmonary Hypertension
  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients ≥ 18 and \<85 years at inclusion,
  • Dyspnea WHO functional class II to IV,
  • Severe precapillary pulmonary hypertension defined by :

    • a mean pulmonary artery pressure (mPAP) >20
    • associated with normal pulmonary artery wedge pressure (PawP ≤15 mmHg)
    • and pulmonary vascular resistance (PVR) >5 WU
  • diagnosed according to current international recommendation with persistent airflow limitation defined by post-bronchodilatator (FEV1) / forced vital capacity (FVC): FEV1/FVC \< 0.70,
  • Naive patients from PDE5i (sildenafil, tadalafil) PH treatments and who did not receive other specific PH treatment in the last 3 months (bosentan, ambrisentan, macitentan, riociguat, epoprostenol, treprostinil, iloprost),
  • Treatments for COPD need to be stable for at least 1 month before screening visit,
  • Patients who fulfill criteria for a supplemental long-term oxygen therapy need to be supplied sufficiently before study entry. The amount of supplemental oxygen and the delivery method need to be stable for at least 1 month before screening visit,
  • Patients who are able to understand and follow instructions and who are able to participate in the study for the entire period,
  • Patients must have given their written to participate in the study after having received adequate previous information and prior to any study-specific procedures,
  • Affiliation to a social security regime,

Exclusion criteria

Exclusion Criteria:

  • Patients with a medical disorder, condition, or history of such that would impair the patient's ability to participate or complete this study in the opinion of the investigator,
  • Patients with underlying medical disorders and anticipated below 12 months (eg active cancer disease with localized and/or metastasized tumor mass),
  • PH not due to chronic respiratory diseases (group 1, 2, 4 or 5 of the clinical classification of PH),
  • Other respiratory diseases: interstitial lung disease, sarcoidosis, lymphangioleiomyomatosis, histiocytosis, or untreated severe sleep apnea disorders,
  • 6-minutes walk distance \< 50 m or patients unable to perform the 6-minutes walk test,
  • Exacerbation of the requiring hospitalization in the last 8 weeks before screening,
  • COPD with mild (> 80% predicted value) or severe ( \<30% predicted value) airflow limitation,
  • Patients listed for lung transplantation at the time of inclusion,
  • Systolic left ventricular dysfunction with \<40% on echocardiography,
  • Patient on AME (state medical aid),
  • Participation in another clinical trial during the preceding 3 months and during the study,
  • Pregnant women, or breast-feeding women, or women with not using a combination of condoms and a safe and highly effective method (hormonal contraception with implants or oral contraceptives, or intrauterine devices) and one month after the end of the study, WOCBP include any woman who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not [defined as amenorrhea ≥ 12 consecutive months; or women on hormone replacement therapy (HRT) with documented serum follicle stimulating hormone (FSH) level > 35 mIU/mL],
  • Patient under guardianship or curatorship

Non-inclusion criteria related to treatment by tadalafil:

  • to tadalafil:

    • Severe renal failure ( \< 30 mL/min/1,73 m2)
    • Severe liver cirrhosis Child-Plugh C
    • Severe systemic hypotension \<90/50
    • Recent myocardial infarction \<90 days
    • Medical history of anterior ischemic optic neuropathy
    • to tadalafil or any of the
  • Concomitant use of potent inhibitors or inducers, soluble guanylate cyclase stimulator (riociguat), other PDE5 inhibitors or nitrates or doxazosin
  • Cardiovascular diseases:

    • aortic and mitral valve disease
    • Pericardial constriction
    • Restrictive or congestive cardiomyopathy
    • Significant left ventricular dysfunction
    • Life-threatening arrhythmias
    • Symptomatic coronary artery disease
    • Uncontrolled hypertension.
    • Angulation of the penis, cavernosal fibrosis, Peyronie's disease or history of priapism
  • Pulmonary or upper respiratory infection requiring antibiotics, or pulmonary embolism in the last 4 weeks before screening
  • Participation in a respiratory rehabilitation program within the 4 weeks prior to screening or scheduled during the study period
  • Right heart failure necessitating catecholamine support within the 4 weeks prior to screening.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Experimental arm

    Oral Tadalafil 40 mg or Tadalafil 20 mg \[(mild or moderate chronic renal failure or liver cirrhosis (Child-Pugh A or B)\].

    Drug: Tadalafil

  • Placebo comparator
    Control arm

    Oral Placebo 40 mg or Placebo 20 mg \[(mild or moderate chronic renal failure or liver cirrhosis (Child-Pugh A or B)\].

    Drug: Placebo

Interventions

  • Oral Tadalafil

    Also known as: Talmanco, ADCIRCA

  • DrugPlacebo

    Oral Placebo

06

What researchers measure

Primary outcomes

  1. 6 minute Walk

    The distance cover in meter during a 6-minute walk at week 16 post-randomization for patients treated with tadalafil compared to placebo

    Time frame: 16 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Oct 2027, 44 months after the start.

Of 31 phase 3 interventional studies under Hypertension, Pulmonary, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 83. This study's planned 44 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2023
First posted
May 6, 2023
StartActual
Feb 1, 2024
Primary completionEst.
Oct 2027
CompletionEst.
Dec 2027
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05844462
Responsible party
Sponsor
First posted
May 6, 2023
Start date
Feb 1, 2024
Primary completion
Oct 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Aug 20, 2026

Study contacts

David Pr MONTANI, PU-PH
Contact
david.montani@aphp.fr
01 45 21 78 85 ext. +33

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tadalafil

Start the discussion